Mylan Executives Unlikely to Lose Pay Over EpiPen Issue

Executives of EpiPen maker Mylan are unlikely to lose pay over the company’s recent $465 million settlement of allegations that it overcharged Medicaid for the lifesaving drug.

from WSJ.com: US Business http://ift.tt/2fiDwKM
via IFTTT